| Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials N Sattar, D Preiss, HM Murray, P Welsh, BM Buckley, AJM de Craen, ... The Lancet 375 (9716), 735-742, 2010 | 3031 | 2010 |
| Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis D Preiss, SRK Seshasai, P Welsh, SA Murphy, JE Ho, DD Waters, ... Jama 305 (24), 2556-2564, 2011 | 1774 | 2011 |
| Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials KK Ray, SRK Seshasai, S Wijesuriya, R Sivakumaran, S Nethercott, ... The Lancet 373 (9677), 1765-1772, 2009 | 1773 | 2009 |
| Interpretation of the evidence for the efficacy and safety of statin therapy R Collins, C Reith, J Emberson, J Armitage, C Baigent, L Blackwell, ... The Lancet 388 (10059), 2532-2561, 2016 | 1738 | 2016 |
| Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials SL Kristensen, R Rørth, PS Jhund, KF Docherty, N Sattar, D Preiss, ... The lancet Diabetes & endocrinology 7 (10), 776-785, 2019 | 989 | 2019 |
| HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials DI Swerdlow, D Preiss, KB Kuchenbaecker, MV Holmes, JEL Engmann, ... The Lancet 385 (9965), 351-361, 2015 | 685 | 2015 |
| Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials J Armitage, C Baigent, E Barnes, DJ Betteridge, L Blackwell, M Blazing, ... The Lancet 393 (10170), 407-415, 2019 | 533 | 2019 |
| Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial SE Nissen, E Stroes, RE Dent-Acosta, RS Rosenson, SJ Lehman, ... Jama 315 (15), 1580-1590, 2016 | 515 | 2016 |
| Statin safety and associated adverse events: a scientific statement from the American Heart Association CB Newman, D Preiss, JA Tobert, TA Jacobson, RL Page, LB Goldstein, ... Arteriosclerosis, thrombosis, and vascular biology 39 (2), e38-e81, 2019 | 478 | 2019 |
| Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations D Preiss, N Sattar Clinical science 115 (5), 141-150, 2008 | 412 | 2008 |
| Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data N Ghouri, D Preiss, N Sattar Hepatology 52 (3), 1156-1161, 2010 | 393 | 2010 |
| Non-alcoholic fatty liver disease N Sattar, E Forrest, D Preiss Bmj 349, 2014 | 357 | 2014 |
| PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study AF Schmidt, DI Swerdlow, MV Holmes, RS Patel, Z Fairhurst-Hunter, ... The lancet Diabetes & endocrinology 5 (2), 97-105, 2017 | 356 | 2017 |
| Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine … SL Kristensen, D Preiss, PS Jhund, I Squire, JS Cardoso, B Merkely, ... Circulation: Heart Failure 9 (1), e002560, 2016 | 336 | 2016 |
| SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? N Sattar, J McLaren, SL Kristensen, D Preiss, JJ McMurray Diabetologia 59, 1333-1339, 2016 | 318 | 2016 |
| GDF15 mediates the effects of metformin on body weight and energy balance AP Coll, M Chen, P Taskar, D Rimmington, S Patel, JA Tadross, I Cimino, ... Nature 578 (7795), 444-448, 2020 | 295 | 2020 |
| Association of lipid fractions with risks for coronary artery disease and diabetes J White, DI Swerdlow, D Preiss, Z Fairhurst-Hunter, BJ Keating, ... JAMA cardiology 1 (6), 692-699, 2016 | 261 | 2016 |
| The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study WG Herrington, D Preiss, R Haynes, M von Eynatten, N Staplin, ... Clinical kidney journal 11 (6), 749-761, 2018 | 224 | 2018 |
| Lipid-modifying therapies and risk of pancreatitis: a meta-analysis D Preiss, MJ Tikkanen, P Welsh, I Ford, LC Lovato, MB Elam, JC LaRosa, ... Jama 308 (8), 804-811, 2012 | 215 | 2012 |
| Empagliflozin in patients with chronic kidney disease EMPA-Kidney Collaborative Group New England Journal of Medicine 388 (2), 117-127, 2023 | 207 | 2023 |
